STONY BROOK, NY -- (Marketwired) -- 04/05/16

Applied DNA Sciences (ADNAS), Inc. (NASDAQ: APDN), a provider of DNA-based supply chain, anti-counterfeiting, anti-theft technology product genotyping and product authentication solutions, today is introducing proprietary enhanced DNA authentication technology specifically quantifying cotton species -- meaning that consumer cotton brands can now determine the amounts of inappropriate blends in their cotton, not just the presence of inferior blends. This is a significant milestone in cotton quantitation using an enhanced DNA authentication technology for fiberTyping® cotton textiles. This technology applies to premium extra long staple ("ELS") cottons that have been "blended" with shorter staple cotton, and labeled as 100% Pima, or 100% Egyptian ELS.

"Consumers unknowingly could buy a mislabeled product," said Dr. Michael E. Hogan, Ph.D., Vice President of Life Sciences at ADNAS. "They could be purchasing a sheet that says it is '100% Egyptian ELS' that is actually not 100% ELS, but, instead, made from yarn containing 30% ELS, and 70% Upland cotton. Our technology provides a method for clearly distinguishing the type of blending, especially in extra long staple cotton products."

During the past eight years, ADNAS' team of international molecular biologists, forensic scientists, quality control and assurance and technical advisors developed the scientific and commercial foundation for validating DNA tests for cotton. This was a significant investment including intellectual property, research, development, technical validation and forensic expertise.

"Simply put, it's about honest cotton," continued Hogan. "Consumers want to buy products from retailers and brands they trust. Our brand partners can be confident the products they source from suppliers contain truthful materials. With our quantitative DNA testing, we will help keep cotton growing, moving and connecting with consumers around the globe not only in the U.S., but also, in Australia, Brazil, China, Egypt, India, Peru and Turkey."

Historically, the goal of select processors of premium cotton fibers (e.g. Egyptian ELS or American Pima) was to buy the highest quality cotton at the lowest price, attempting to meet product specifications by blending bales with different fiber qualities and types. Blending of premium extra long staple cotton with shorter staple non-ELS upland cotton occurs when brands search for higher profit margins and there is a lack of available high quality extra long staple fiber. This blending of different fiber types results in impure products being labeled and sold as 100% ELS cotton, violating US and international laws.

"It has been reported that ELS cotton grown in Egypt is experiencing difficulties due to mixing of pure Egyptian ELS cotton seeds with poorer quality seeds," noted Hogan. "At recent global industry meetings, discussions were held on the standards for Egyptian cotton and the alleged fraudulent practices taking place now. Our fiberTyping testing enables proper diagnosis of these widely blended, counterfeited textiles."

Government agencies like the Federal Trade Commission established clear guidelines protecting the consumer by ensuring that products are based on accurate information on product origin, construction, quality, and care. The disclosure of fiber content is integral to trade in textiles and apparel; it is incumbent upon the manufacturer to know, and to correctly report, fiber content in both documentation and on product labels.

"This is a critical tipping point," said MeiLin Wan, Vice President of Textile Sales at ADNAS. "It is important to provide quantitative results for cotton yarns and fabrics, specifically for greige (gray and beige) yarn and fabric. Since they are unprocessed, the ability to extract DNA and precisely determine the quantity of ELS DNA, Upland DNA or a blend, is helpful to determine if the product is 100% pure. This is the tip of the iceberg; expect more technical innovations from Applied DNA in the coming year."

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Our patented DNA-based solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature® DNA describes the platform ingredient that is at the heart of a family of uncopiable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW. 

Forward-Looking Statements
The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015, and our subsequent quarterly report on Form 10-Q filed on February 10, 2016 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor Contact:
Debbie Bailey
631-240-8817
debbie.bailey@adnas.com

Media Contact:
Kristen Bujold
CGPR
781-639-4924, Ext. 115
kristenb@cgprpublicrelations.com

Program Contact:
MeiLin Wan
631-240-88849
meilin.wan@adnas.com

Web: www.adnas.com
Twitter: @APDN